FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

The Harvard Drug Group Gabapentin Capsules Recall

Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packag…

The Harvard Drug Group LLC · Dublin, OH

Risk level
Class II
Reported by FDA
Oct 29, 2025
Recall ID
D-0030-2026
Check your lot numberHow we source this data

Summary

The Harvard Drug Group recalled Gabapentin Capsules starting Oct 10, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0030-2026 on Oct 29, 2025. Reason: Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity . Status: Ongoing.

Why it was recalled

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Product description

Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61

Lot numbers, UPCs & expiration codes

Lot # M04950, Exp Date: 01/2026; Lot # M04989, M04990, Exp Date: 02/2026; Lot # M05056, Exp Date: 04/2026; Lot # M05150, Exp Date: 07/2026; Lot # M05290, Exp Date: 11/2026; Lot # M05312, M05342, Exp Date: 01/2027; Lot # M05369, M05386, Exp Date: 02/2027.

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0030-2026
Classification
Class II
Status
Ongoing
Recall initiated
Oct 10, 2025
FDA report date
Oct 29, 2025
Recall type
Voluntary: Firm initiated
Recalling firm
The Harvard Drug Group LLC

Original FDA data

Every field from FDA enforcement report D-0030-2026, exactly as published.

Show all FDA fields
City
Dublin
State
OH
Status
Ongoing
Country
United States
Event ID
97777
Address
7000 Cardinal Pl
Code information
Lot # M04950, Exp Date: 01/2026; Lot # M04989, M04990, Exp Date: 02/2026; Lot # M05056, Exp Date: 04/2026; Lot # M05150, Exp Date: 07/2026; Lot # M05290, Exp Date: 11/2026; Lot # M05312, M05342, Exp Date: 01/2027; Lot # M05369, M05386, Exp Date: 02/2027.
Postal code
43017-1091
Report date
Oct 29, 2025
Product type
Drugs
Recall number
D-0030-2026
Classification
Class II
Recalling firm
The Harvard Drug Group LLC
Reason for recall
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .
Voluntary / mandated
Voluntary: Firm initiated
Product description
Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61
Distribution pattern
US Nationwide.
Recall initiation date
Oct 10, 2025
Center classification date
Oct 17, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0030-2026, published Oct 29, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls